Global Gout Therapeutics Market Size (2024 - 2029)

The Gout Therapeutics market is projected to experience significant growth, driven by factors such as the increasing adoption of biologics, advancements in imaging technologies, and rising research and development activities in regenerative medicines. The market's expansion is further supported by the growing prevalence of gout, influenced by lifestyle factors like alcohol consumption and obesity, which elevate the risk of developing the condition. Despite these growth drivers, challenges such as the side effects of therapeutics and high indirect costs pose obstacles to market expansion. The COVID-19 pandemic has also negatively impacted the market by delaying diagnoses and complicating treatment protocols for gout patients.

Market Size of Global Gout Therapeutics Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Gout Therapeutics Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 15.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Gout Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Gout Therapeutics Market Analysis

The Gout Therapeutics market is anticipated to grow with a CAGR of 15.5%, over the forecast period (2022 - 2027).

The COVID-19 pandemic has significantly impacted market growth. The onset of the COVID-19 pandemic has caused a nationwide lockdown with the suspension of non-urgent scheduled visits and hospitalizations which resulted in the delayed diagnosis of patients suffering from gout. For instance, according to an article published by the Rheumatology Journal, in March 2022, titled " Gout and the COVID-19 pandemic', due to concomitant cardiometabolic disorders, people with gout are expected to be at an elevated risk of adverse outcomes following COVID-19 infection. In addition, as per the same source, the COVID-19 epidemic has posed several challenges for people suffering from gout as well as a lack of guidance on the management of gout during the pandemic and scant research evaluating the effects of COVID-19 infection on gout sufferers has impacted the growth of the studied market during the pandemic. Additionally, according to an article published by the Annals of Rheumatic Diseases, in March 2022, titled 'Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination', it has been observed that the COVID-19 vaccine was negatively associated with colchicine prophylaxis and was linked to an elevated risk of gout flares, which primarily appeared in the first month following each dosage. Thus, COVID-19 has a negative impact on the treatment as well as the supply of therapeutics related to gout.

The factors attributed to the growth of the market are the growing adoption of biologics and rising research and development activities on regenerative medicines, the rising prevalence of gout with increasing alcohol consumption, and technological advancements in imaging modalities that improved the understanding of gout.

In addition, the factors that increase the risk of developing gout are obesity, dietary factors, comorbid conditions, and novel associations of gout with other comorbidities, such as erectile dysfunction, atrial fibrillation, obstructive sleep apnea, osteoporosis, and venous thromboembolism have been reported. For instance, according to 2022 statistics published by World Obesity Federation, it has been observed that 31.5% of men and 40.2% of women are living with obesity in Mexico in 2020. Also, according to the Eurostat report in July 2021, more than half (53%) were overweight (36% pre-obese and 17% obese) in Europe in 2020. As per the same source, the highest share of the obese population was found in the people aged 65 to 74 (66%) and the lowest among those aged 18 to 24 (25%). Thus, a high body mass index increases the risk of developing gout by increasing the serum uric acid level in the body and leads to hyperuricemia which decreased the renal secretion of urate. This is expected to increase the demand for effective treatment and therapeutics which is in turn anticipated to propel the market growth.

The rising incidence and prevalence of gout among the population are also contributing to the market growth. For instance, according to an article published by the Annals of Rheumatic Diseases, in June 2021, titled 'Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021', it has been observed that the prevalence rate of gout has been increased from 0.98%in 1997 to 2.33% in 2021. As per the same source, the incidence of gout increased by 0.98/1,000 persons in 2021. Thus, the high burden of gout is expected to increase the demand for drugs treating this condition, which is anticipated to fuel the market growth over the forecast period.

However, the side effects of gout therapeutics drugs and the high indirect costs of gout therapeutics are the factors that are impeding the growth of the market.

Gout Therapeutics Industry Segmentation

As per the scope of the report, gout is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in the blood. The acid can form needle-like crystals in a joint and cause sudden, severe episodes of pain, tenderness, redness, warmth, and swelling. The Gout Therapeutics Market is segmented By Drug Class (Anti-hyperuricemic Agents (Urate-Lowering Drugs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, and Other Drug Classes), Application (Acute Gout and Chronic Gout), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Antihyperuricemic Agents (Urate-Lowering Drugs)
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Other Drug Classes
By Application
Acute Gout
Chronic Gout
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Gout Therapeutics Market Size Summary

The gout therapeutics market is poised for significant growth, driven by the increasing prevalence of gout and the rising adoption of biologics and advanced imaging technologies. The market has faced challenges due to the COVID-19 pandemic, which led to delayed diagnoses and treatment disruptions. However, the demand for effective gout treatments is expected to rise, fueled by factors such as the growing incidence of obesity-related comorbidities and the increasing awareness of gout's impact on health. The market is characterized by a diverse range of therapeutics, including antihyperuricemic agents and urate-lowering drugs, which are gaining traction due to their efficacy in managing gout symptoms and preventing flare-ups.

North America is anticipated to hold a significant share of the gout therapeutics market, supported by a robust healthcare infrastructure and substantial healthcare expenditure. The region's market growth is further bolstered by the introduction of new products and therapies, as well as strategic partnerships and clinical trials aimed at developing innovative treatments. The competitive landscape of the market is marked by the presence of major players such as Lannett Company, Horizon Therapeutics plc, and Takeda Pharmaceutical Company Ltd, who are actively engaged in expanding their product offerings and enhancing treatment outcomes for gout patients. As the market continues to evolve, it is expected to witness increased company activities and government initiatives, contributing to its overall expansion over the forecast period.

Explore More

Global Gout Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Adoption of Biologics and Increasing R&D on Regenerative Medicines

      2. 1.2.2 Rising Prevalence of Gout with Increasing Alcohol Consumption

      3. 1.2.3 Technological Advancements in Imaging Modalities Improved Understanding of Gout

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects of Gout Therapeutic Drugs

      2. 1.3.2 High Indirect Costs of Gout Therapeutics

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value in USD million)

    1. 2.1 By Drug Class

      1. 2.1.1 Antihyperuricemic Agents (Urate-Lowering Drugs)

      2. 2.1.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)

      3. 2.1.3 Corticosteroids

      4. 2.1.4 Colchicine

      5. 2.1.5 Other Drug Classes

    2. 2.2 By Application

      1. 2.2.1 Acute Gout

      2. 2.2.2 Chronic Gout

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Gout Therapeutics Market Size FAQs

The Global Gout Therapeutics Market is projected to register a CAGR of 15.5% during the forecast period (2024-2029)

Lannett Company, Inc, Horizon Therapeutics plc, Takeda Pharmaceutical Company Ltd, GlaxoSmithKline Plc and Regeneron Pharmaceuticals, Inc. are the major companies operating in the Global Gout Therapeutics Market.

Gout Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)